[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Gilead Sciences insider sale reported on Form 4: Johanna Mercier, Chief Commercial Officer, disposed of 3,000 shares of GILD common stock on 09/15/2025 at a price of $113.57 per share under a pre-established Rule 10b5-1 trading plan adopted February 20, 2025. Following the transaction Mercier beneficially owns 113,193 shares. The Form 4 was signed by Edward S. Son by power of attorney on 09/16/2025. The filing documents a single non-derivative sale and includes the Rule 10b5-1 disclosure indicating the trade was executed pursuant to an established plan.

Insights

Securities Analyst

TL;DR: Routine officer sale under a 10b5-1 plan; not an unusual governance signal by itself.

The reported sale is a straightforward non-derivative disposition of 3,000 common shares by the Chief Commercial Officer at $113.57 per share, executed via a Rule 10b5-1 plan adopted February 20, 2025. The post-transaction beneficial ownership remains 113,193 shares, indicating continued meaningful ownership. Because this trade is pre-planned and the filing discloses no additional transactions or derivative activity, it represents a procedural liquidity event rather than a clearly material change to insider alignment with shareholders.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 requirements; 10b5-1 plan disclosure reduces concerns about opportunistic timing.

The Form 4 properly reports the officer-level sale and cites the controlling Rule 10b5-1 trading plan adoption date. The signature by power of attorney is documented. There are no amendments or additional filings referenced. From a governance perspective, timely public reporting and the 10b5-1 attribution support compliance with insider trading rules, and the single-line filing contains the standard explanatory remark.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		3,000	D	$113.57	113,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Johanna Mercier	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Johanna Mercier report on the GILD Form 4?

The Form 4 reports a sale of 3,000 GILD common shares on 09/15/2025 at $113.57 per share.

Was the sale by Johanna Mercier part of a trading plan?

Yes. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

How many GILD shares does Johanna Mercier beneficially own after the reported sale?

Following the reported transaction Mercier beneficially owns 113,193 shares.

Who signed the Form 4 for Johanna Mercier and when?

The Form 4 was signed by Edward S. Son by power of attorney on 09/16/2025.

Does the Form 4 report any derivative transactions for Mercier?

No. The filing lists only a non-derivative sale of common stock and contains no derivative transactions.